Provided by Tiger Fintech (Singapore) Pte. Ltd.

Catalyst Pharmaceuticals

21.89
+0.35001.62%
Post-market: 22.000.1100+0.50%19:57 EDT
Volume:1.02M
Turnover:22.19M
Market Cap:2.67B
PE:13.96
High:22.05
Open:21.58
Low:21.40
Close:21.54
Loading ...

Jim Cramer on Catalyst Pharmaceuticals (CPRX): ‘That’s My Kind of Stock!’

Insider Monkey
·
27 Mar

Catalyst Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
27 Mar

With 81% ownership in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), institutional investors have a lot riding on the business

Simply Wall St.
·
26 Mar

Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains?

Zacks
·
25 Mar

Catalyst Pharmaceuticals Inc. Stock Advances 6.2%, Outperforms Competitors

Dow Jones
·
25 Mar

Catalyst Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
21 Mar

Catalyst Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
18 Mar

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Zacks
·
17 Mar

Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Healthcare Stock For Long-Term Investment?

Insider Monkey
·
14 Mar

Truist Financial Keeps Their Buy Rating on Catalyst Pharma (CPRX)

TIPRANKS
·
14 Mar

Catalyst Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
14 Mar

Catalyst Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
11 Mar

Catalyst Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
07 Mar

We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Robust Earnings Are Conservative

Simply Wall St.
·
05 Mar

Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference

GlobeNewswire
·
04 Mar

Catalyst Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
04 Mar

Catalyst Pharmaceuticals Is Maintained at Outperform by Baird

Dow Jones
·
03 Mar

Catalyst Pharmaceuticals Inc. Stock Rallies 5.7%, Outperforms Competitors

Dow Jones
·
01 Mar

Stock Track | Catalyst Pharmaceuticals Stock Soars 5.03% on Strong Full-Year 2024 Earnings

Stock Track
·
01 Mar

Oppenheimer Adjusts Price Target on Catalyst Pharmaceuticals to $32 From $31, Maintains Outperform Rating

MT Newswires Live
·
28 Feb